Abstract | BACKGROUND AND OBJECTIVES: METHODS: We conducted an open-label, prospective pilot study using 60 units of botulinum toxin A injected intracarpally in patients with primary CTS. Changes in median nerve conduction velocities, distal latencies, compound muscle action potentials and visual analogue scale (VAS) pain scores were evaluated for 3 months following injection. All adverse experiences, reported spontaneously or observed directly by the investigator, were recorded. RESULTS: Five women aged 52.2 +/- 2.5 years with 1-2 years' history of CTS were enrolled. Botulinum toxin A was well tolerated and safe. No exacerbated hand weakness was observed in any of the patients. At 3 months, pain was lessened in three patients, remained static in one patient, and was aggravated in one patient. The VAS pain score showed a trend to improvement during the 3 months of follow-up, although it did not reach statistical significance (p = 0.2). CONCLUSION: Our data suggest long-lasting antinociceptive effects of botulinum toxin A rather than electrophysiological restoration in patients with CTS. Intracarpal injection of botulinum toxin A was shown to be well tolerated and safe. A double-blind, placebo-controlled trial of botulinum toxin A in CTS is warranted since the current study may have been confounded by the placebo effect of intracarpal injection.
|
Authors | Ching-Piao Tsai, Chih-Yang Liu, Kon-Ping Lin, Kai-Chen Wang |
Journal | Clinical drug investigation
(Clin Drug Investig)
Vol. 26
Issue 9
Pg. 511-5
( 2006)
ISSN: 1173-2563 [Print] New Zealand |
PMID | 17163284
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Botulinum Toxins, Type A
(therapeutic use)
- Carpal Tunnel Syndrome
(drug therapy)
- Female
- Humans
- Middle Aged
- Prospective Studies
|